Every 8-K that Xenetic Biosciences, Inc. (XBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow XBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XBIO filings page.
Xenetic Biosciences (XBIO) announced an updated investor presentation for its pending share exchange transaction with Santersus AG. The proposed transaction is subject to Xenetic stockholder approval and is expected to close in Q4 2026. At closing, Santersus would become a wholly owned subsidiary and continue as the combined company’s operating business; the combined company is expected to trade on Nasdaq as SNTS. The presentation lists negotiated valuations of $21 million for Xenetic and $120 million for Santersus, with a total estimated transaction valuation of $141 million. The Xenetic valuation assumes $0 Net Cash and is subject to adjustment. It estimates Santersus shareholders would own approximately 85% and Xenetic stockholders approximately 15%, subject to adjustment, and illustrates approximately 14,552,566 new Xenetic shares issued at closing; actual issuance is determined by the Exchange Ratio.
The presentation also reports that a retrospective analysis of 10 NucleoCapture compassionate-use cases in SLE showed median SLEDAI-2K of 17.5 before and 8.0 after three treatments (p=0.009).
Xenetic Biosciences, Inc. (XBIO) entered into a Share Exchange Agreement to acquire all of the outstanding share capital of Swiss company Santersus AG in an all‑stock transaction, with Santersus becoming a wholly owned subsidiary. At closing, Santersus shareholders are expected to own approximately 85% and existing Xenetic stockholders about 15% of the combined company on a fully diluted, as‑converted basis, subject to net cash and other adjustments. The combined company is expected to be renamed Santersus Bio, Inc. and listed on the Nasdaq Capital Market under the symbol “SNTS”, with an eight‑member board (six designated by Santersus and two by Xenetic) and Santersus CEO James Ladtkow leading management. Closing is targeted for the fourth quarter of 2026 and is conditioned on Xenetic stockholder approval, effectiveness of a resale Form S‑1, Nasdaq listing approval for the new shares, and other customary conditions; Xenetic may owe a $500,000 termination fee and up to $300,000 in expense reimbursement in certain break scenarios.
Xenetic Biosciences, Inc. reported financial results for the quarter ended June 30, 2026 and highlighted progress on its proprietary DNase immuno-oncology platform. Royalty revenue for the quarter was approximately $0.7 million, up about 12% from approximately $0.6 million in the prior-year period, contributing to approximately $1.5 million in royalty revenue during the first six months of 2026.
Research and development expenses decreased to approximately $0.6 million, while general and administrative expenses rose to approximately $1.1 million, largely due to higher legal costs tied to an ongoing strategic review process. Net loss for the quarter was approximately $0.9 million. The company ended the second quarter with approximately $6.5 million in cash and cash equivalents, compared to approximately $7.9 million as of December 31, 2025, and continues to advance its DNase platform through preclinical, translational and collaborative research efforts.
Xenetic Biosciences reported first quarter 2026 results showing higher royalty revenue and a smaller loss while advancing its DNase oncology platform. Royalty revenue for the three months ended March 31, 2026 rose about 36% to approximately $0.8 million from about $0.6 million a year earlier, mainly from its sublicense with Takeda.
Research and development expenses fell to roughly $0.7 million and general and administrative expenses edged down to about $0.6 million, contributing to a reduced net loss of approximately $0.5 million versus about $0.9 million in 2025. The company ended the quarter with around $7.3 million in cash and continues to evaluate strategic alternatives while progressing translational research, investigator-initiated studies and manufacturing readiness for its DNase I immuno-oncology program.
Xenetic Biosciences approved a new equity award for its Interim Chief Executive Officer and Chief Financial Officer, James Parslow, under its Amended and Restated Equity Incentive Plan. The grant consists of 100,000 shares of restricted stock, documented in a restricted stock award agreement dated April 21, 2026.
Of these shares, 7,000 vest immediately on the grant date. The remaining 93,000 shares will vest in three equal installments on each of the first, second, and third anniversaries of April 21, 2026. This structure is designed to tie Mr. Parslow’s compensation to ongoing service over several years.
Xenetic Biosciences reported a full-year 2025 net loss of approximately $2.7 million, as it continued investing in its DNase-based immuno-oncology programs targeting difficult-to-treat cancers. Royalty revenue from its sublicense with Takeda grew about 19% to $3.0 million, up from $2.5 million in 2024.
Research and development expenses were $3.1 million, down from $3.3 million, partly because a $0.7 million impairment recorded in 2024 did not recur, while DNase process development spending increased. General and administrative costs fell about 20% to $2.7 million. Xenetic ended 2025 with roughly $7.9 million in cash, about $1.7 million higher than the prior year, primarily from net proceeds of around $4.0 million raised in an October 2025 underwritten public offering.
Xenetic Biosciences, Inc. reported that its 2025 Annual Meeting of Stockholders, originally adjourned from December 11, 2025 to January 8, 2026 to seek more proxies and achieve a quorum, was again adjourned on January 8, 2026 without any business being conducted because a sufficient number of shares was not represented.
The company plans to reconvene the Annual Meeting at a future date and time that has not yet been set and will give stockholders the required advance notice before the new meeting.
Xenetic Biosciences, Inc. filed an 8-K announcing it furnished a press release with results for the three months ended September 30, 2025. The press release is included as Exhibit 99.1 and incorporated by reference into Item 2.02.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes customary forward-looking statements language outlining risk factors and cautions.
Xenetic Biosciences entered an underwriting agreement for an underwritten public offering of 735,000 shares of common stock at $6.12 per share. The company estimates approximately $3.9 million in net proceeds, to be used for working capital, general corporate purposes, and advancement of its DNase technology.
The offering is being conducted under Xenetic’s effective Form S-3 shelf registration statement (File No. 333-282756). The company agreed to a 60-day restriction on issuing or selling additional common stock or convertible securities following the agreement date. Canaccord Genuity LLC is the representative of the underwriters.
Xenetic Biosciences, Inc. reported that it issued a press release with its financial results for the three months ended June 30, 2025. The company furnished this press release as an exhibit to a current report, making the quarter’s performance details available to investors through that document.
The disclosure also includes an extensive caution about forward-looking statements, noting that expectations are subject to numerous risks and uncertainties described in Xenetic’s other SEC reports. The company’s common stock continues to trade on The Nasdaq Stock Market under the symbol XBIO.